Compare Royal Caribbean Cruises Ltd (RCL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs TransMedics Group Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $279.05 (market cap $75.26B), while TransMedics Group Inc trades at $77.75 (market cap $2.74B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 27.5× TransMedics Group Inc's market cap, and Royal Caribbean Cruises Ltd pays a 2.13% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and TransMedics Group Inc for 24 Days on average.
| RCL | TMDX | |
|---|---|---|
Market Cap | $75.26B | $2.74B |
Volume | 1,958,628 | 949,331 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $150.42 |
52-Week Low | $230.30 | $61.99 |
Typical Hold Time | 85 Days | 24 Days |
Enterprise Value | $97.91B | $3.13B |
Dividend Yield | 2.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $280.65, down 0.61% on the day, with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 2025 revenue of $17.93B, net income of $4.27B (23.54% margin), and consistent earnings beats in recent quarters. Recent news highlights include a $3B investment in Sandals Resorts and positive analyst sentiment with 52.83% buy ratings.
RCL presents a compelling growth story with strong profitability and expansion initiatives, though risks include high debt levels and fuel cost exposure. The consensus price target of $346.67 suggests 23.5% upside potential, supported by improving cash flow trends and strategic diversification into resort operations.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
